All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
EquityEquity IPOs

Molecular Partners latest IPO failure, but others get through

Swiss biotech firm Molecular Partners became the latest victim of the recent bout of volatility in Europe’s markets, as it put its planned listing on hold on Tuesday. More deals could yet fail, bankers said.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree